A systematic review and meta-analysis of venous thrombosis risk among users of combined oral contraception.

Existing Reviews

Please note, new claims can take a short while to show up.

No claims yet.

Annotation Summary

Term Occurence Count Dictionary
thrombosis 9 angiologydiseases

There are not enough annotations found in this document to create the proximity graph.

Review

Having read the paper, please pick a pair of statements from the paper to indicate that a drug and disease are related.

Select Drug Character Offset Drug Term Instance
Select Disease Character Offset Disease Term Instance
thrombosis 108 International Journal of Gynaecology and ObstetricsA systematic review and meta‐analysis of venous thrombosis risk among users of combined oral contraceptionAlternative Title: dragoman ET AL.Monica V. DragomanNaomi
thrombosis 1123 database inception through September 15, 2016, by combining search terms for oral contraception and venous thrombosis .Selection criteriaStudies reporting VTE risk estimates among healthy users of progestogen‐containing
thrombosis 2617 women‐years), combined oral contraceptive (COC) use can increase the risk for VTE, including deep venous thrombosis and pulmonary embolism, compared with nonuse.1, 2 Nonetheless, the incidence of VTE remains low (8–10
thrombosis 2921 incidence of VTE during pregnancy and the postpartum period.3, 4 The effect of COCs on the risk of thrombosis was traditionally thought to be solely related to the effects of estrogen on hemostatic factors. However,
thrombosis 4655 inception through September 15, 2016, using a combination of search terms for oral contraception and venous thrombosis (Table S1). In addition, the reference lists from identified studies and key review articles were hand‐searched
thrombosis 6293 uncommonly prescribed.For the outcomes, the present analysis included studies that examined deep venous thrombosis with or without pulmonary embolism; deep venous thrombosis, pulmonary embolism, and venous thrombosis
thrombosis 6352 included studies that examined deep venous thrombosis with or without pulmonary embolism; deep venous thrombosis , pulmonary embolism, and venous thrombosis at other sites (cerebral vein, portal vein, caval vein, or
thrombosis 6395 thrombosis with or without pulmonary embolism; deep venous thrombosis, pulmonary embolism, and venous thrombosis at other sites (cerebral vein, portal vein, caval vein, or renal vein); or unspecified VTE. Studies
thrombosis 22677 formulations, and to evaluate whether these changes translate into clinical differences in the risk of thrombosis .The present meta‐analysis used adjusted risk estimates to reduce potential confounding. Four other

You must be authorized to submit a review.